Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
Darren R FeldmanYasser GedChung-Han LeeAndrea KnezevicAna M MolinaYing-Bei ChenJoshua ChaimDevyn T CoskeySamuel MurraySatish K TickooVictor E ReuterSujata PatilHan XiaoJahan AghalarArlyn J ApolloMaria I CarloRobert J MotzerMartin H VossPublished in: Cancer (2020)
The expansion cohort results confirm robust activity of everolimus plus bevacizumab in metastatic pRCC variants, supporting this regimen as a standard option for this patient population.